[go: up one dir, main page]

FI880428L - Ytantigener av hepatit b virus och hybridantigener innehaollande desamma. - Google Patents

Ytantigener av hepatit b virus och hybridantigener innehaollande desamma. Download PDF

Info

Publication number
FI880428L
FI880428L FI880428A FI880428A FI880428L FI 880428 L FI880428 L FI 880428L FI 880428 A FI880428 A FI 880428A FI 880428 A FI880428 A FI 880428A FI 880428 L FI880428 L FI 880428L
Authority
FI
Finland
Prior art keywords
ytantigener
hybridantigener
hepatitis
och
virus
Prior art date
Application number
FI880428A
Other languages
English (en)
Other versions
FI880428A7 (fi
FI880428A0 (fi
Inventor
Teresa Cabezon
Wilde Michael De
Nigel Harford
Marjolene Crabeel
Apolonia Rutgers
Original Assignee
Smith Kline Rit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline Rit filed Critical Smith Kline Rit
Publication of FI880428A0 publication Critical patent/FI880428A0/fi
Publication of FI880428A7 publication Critical patent/FI880428A7/fi
Publication of FI880428L publication Critical patent/FI880428L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
FI880428A 1987-01-30 1988-01-29 Ytantigener av hepatit b virus och hybridantigener innehaollande desamma. FI880428L (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US932587A 1987-01-30 1987-01-30

Publications (3)

Publication Number Publication Date
FI880428A0 FI880428A0 (fi) 1988-01-29
FI880428A7 FI880428A7 (fi) 1988-07-31
FI880428L true FI880428L (fi) 1988-09-13

Family

ID=21736956

Family Applications (1)

Application Number Title Priority Date Filing Date
FI880428A FI880428L (fi) 1987-01-30 1988-01-29 Ytantigener av hepatit b virus och hybridantigener innehaollande desamma.

Country Status (20)

Country Link
EP (1) EP0278940A3 (fi)
JP (1) JPS6463382A (fi)
KR (1) KR880009130A (fi)
CN (1) CN1031395A (fi)
AP (1) AP56A (fi)
AU (1) AU1093088A (fi)
DD (3) DD285612A5 (fi)
DK (1) DK43188A (fi)
FI (1) FI880428L (fi)
HU (1) HUT50876A (fi)
IL (1) IL85216A0 (fi)
MA (1) MA21169A1 (fi)
NO (1) NO880395L (fi)
NZ (1) NZ223297A (fi)
OA (1) OA08801A (fi)
PT (1) PT86640B (fi)
SU (1) SU1746887A3 (fi)
TN (1) TNSN88004A1 (fi)
YU (1) YU17488A (fi)
ZA (1) ZA88488B (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300213A1 (en) * 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Hepatitis a viral peptide particle immunogens
NZ228774A (en) * 1988-04-25 1991-05-28 Phillips Petroleum Co Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
EP0345792A3 (en) * 1988-06-10 1991-05-02 F. Hoffmann-La Roche Ag Htlv-i / hiv-1 fusion proteins
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
EP0421626A1 (en) * 1989-09-19 1991-04-10 Merck & Co. Inc. Vaccine for aids and hepatitis B
US5130247A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
US5130248A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAg
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
ES2129461T3 (es) * 1991-11-16 1999-06-16 Smithkline Beecham Biolog Proteina hibrida entre cs de plasmodium y hbsag.
DE69231693T2 (de) * 1991-12-23 2001-05-31 Bayer Corp., East Walpole Hbv amplifizierungssonden zur verwendung in hybridisierungssandwichassay in der lösungsphase
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6169171B1 (en) 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
US5928902A (en) * 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
DK0891982T3 (da) * 1992-03-06 2007-09-03 Innogenetics Nv HIV-peptider
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
CA2118026A1 (en) * 1992-04-14 1993-10-28 Guy T. Layton Induction of ctl responses
RU2160120C2 (ru) 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
WO1997038087A2 (en) 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
CA2266656A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CN100406060C (zh) 1998-10-16 2008-07-30 史密丝克莱恩比彻姆生物有限公司 一种佐剂组合物
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
CN100381171C (zh) * 2004-12-30 2008-04-16 成都生物制品研究所 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
EP2441470B1 (en) 2006-03-14 2014-05-07 Oregon Health and Science University Methods for producing an immune response to tuberculosis
US8956625B2 (en) 2006-09-07 2015-02-17 Glaxosmithkline Biologicals, S.A. Inactivated polio vaccines
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CA2678404C (en) 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
CA2685506A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
CA2994694A1 (en) 2015-08-03 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
CN119780431A (zh) * 2025-03-11 2025-04-08 泰州蕾灵百奥生物科技有限公司 一种用于检测猪流行性腹泻的试剂盒及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2145092B (en) * 1983-01-28 1988-04-07 Univ New York Protective peptide antigen
AU584580B2 (en) * 1982-09-08 1989-06-01 Smith Kline - Rit Hepatitis B virus vaccine
ATE73349T1 (de) * 1984-06-18 1992-03-15 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
EP0401941A3 (en) * 1984-07-11 1991-04-17 Takeda Chemical Industries, Ltd. Hepatitis b virus surface antigen and production thereof
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
DE3584866D1 (de) * 1984-09-12 1992-01-23 Chiron Corp Hybridpartikel-immunogene.
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
DE3689899T2 (de) * 1985-04-08 1994-09-15 Amgen Verfahren und hybridpromotor zur steuerung der exogenen gentranskription.
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein

Also Published As

Publication number Publication date
FI880428A7 (fi) 1988-07-31
ZA88488B (en) 1988-10-26
YU17488A (en) 1991-02-28
MA21169A1 (fr) 1988-10-01
NZ223297A (en) 1991-06-25
HUT50876A (en) 1990-03-28
NO880395D0 (no) 1988-01-29
TNSN88004A1 (fr) 1990-07-10
IL85216A0 (en) 1988-07-31
EP0278940A3 (en) 1988-12-07
AP8800078A0 (en) 1987-11-01
AU1093088A (en) 1988-08-04
DD284899A5 (de) 1990-11-28
DD285994A5 (de) 1991-01-10
SU1746887A3 (ru) 1992-07-07
EP0278940A2 (en) 1988-08-17
FI880428A0 (fi) 1988-01-29
DK43188A (da) 1988-07-31
JPS6463382A (en) 1989-03-09
DD285612A5 (de) 1990-12-19
CN1031395A (zh) 1989-03-01
OA08801A (fr) 1989-03-31
PT86640A (pt) 1988-02-01
DK43188D0 (da) 1988-01-28
KR880009130A (ko) 1988-09-14
PT86640B (pt) 1992-01-31
NO880395L (no) 1988-08-01
AP56A (en) 1989-09-26

Similar Documents

Publication Publication Date Title
FI880428L (fi) Ytantigener av hepatit b virus och hybridantigener innehaollande desamma.
FI880693A0 (fi) Foerfarande foer framstaellning av en roekningsartikel och komponenter foer anvaendning daeri.
FI923443A0 (fi) Foereningar och foerfarande foer inhibering av hiv och liknande virus.
FI894006L (fi) Agonister av neuropeptid y och partiella agonister.
FI870979A0 (fi) Filterkonstruktion och foerfarande foer bildande av filterkonstruktion.
FI880802A0 (fi) T- och b-cellepitoper av pre-s-regionen av hepatitis b-virusytantigen.
FI87024B (fi) Foerfarande foer styrning av en kortsluten asynkronmotor och styrkrets.
FI871274A7 (fi) Foerfarande och anordning foer styrning av bergborrning.
FI871709A7 (fi) Foerfarande och anordning foer utraetning av gjutna anoder.
FI870287L (fi) Paelsdjursfoder och foerfarande foer framstaellning av detsamma.
FI891941A0 (fi) Uttryckande av hepatitis b pres2-protein i metylotropa jaester.
FI870184A0 (fi) Akustiskt stroemningsmaetningsfoerfarande och anordning foer tillaempning av detta.
FI871739A7 (fi) Foerfarande och anordning foer aotskiljning av vaetskor.
FI874062L (fi) Lpv-baserade vaevnadsspecifika virusvektorer och anvaendning av dessa.
FI871730L (fi) Foerfarande foer framstaellning av hemicellulosahydrolysat och specialmassa.
FI870747A7 (fi) Foerfarande och anordning foer foerbaettring av reglering och behandling av fibersuspensionsstroemning.
FI873128L (fi) Foerfarande och foerhindrande av virusreplikation och sjukdom.
FI871034A7 (fi) Foerfarande och anordning foer uppstapling av cellulosabalar.
FI861164A0 (fi) Anordning foer flyttning och tipping av bytbar flak.
FI863960A0 (fi) Anordning foer flyttning och tipping av bytbart flak.
FI80863B (fi) Foerfarande och anordning foer lagring av pappersrullar.
FI870943A0 (fi) Foerfarande foer framstaellning av raka kanaldelar och en kanaldel.
FI871306A0 (fi) Foerfarande och anordning foer fyllning och foerslutning av en flervaeggad ventilpaose.
FI870878A0 (fi) Foerfarande och anordning foer begraensning av djurs roerelse.
FI871323A0 (fi) Anordning foer avkvistning och kapning av stockar serievis.

Legal Events

Date Code Title Description
FD Application lapsed
MM Patent lapsed

Owner name: SMITHKLINE BIOLOGICALS S.A.